These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3100015)

  • 1. Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer.
    Vorobiof DA; Falkson G
    Cancer; 1987 Feb; 59(4):688-9. PubMed ID: 3100015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial.
    Falkson G; Vorobiof DA
    J Clin Oncol; 1987 Sep; 5(9):1419-23. PubMed ID: 3114438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung metastases of prostate carcinoma cleared by intranasal GRH analogue.
    Volmer MC; Lascano A; Poggi U; Argüelles AE
    Lancet; 1985 Jun; 1(8444):1507. PubMed ID: 2861433
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone analog, buserelin (HOE 766).
    Koutsilieris M; Ackman CF
    Prostate; 1987; 10(1):19-24. PubMed ID: 3103114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer.
    Lopez M; Natali M; Di Lauro L; Vici P; Pignatti F; Carpano S
    Cancer; 1993 Jul; 72(2):502-5. PubMed ID: 8319180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buserelin in premenstrual syndrome.
    Hussain SY; Massil JH; Matta WH; Shaw RW; O'Brien PM
    Gynecol Endocrinol; 1992 Mar; 6(1):57-64. PubMed ID: 1580169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic use of a gonadotropin releasing hormone analogue in breast cancer].
    Kahán Z; Falkay G
    Orv Hetil; 1990 May; 131(19):1033-6. PubMed ID: 2111904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
    Plowman PN; Nicholson RI; Walker KJ
    Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
    Doberauer C; Niederle N; Schmidt CG
    Cancer; 1988 Aug; 62(3):474-8. PubMed ID: 3134119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty.
    Holland FJ; Fishman L; Costigan DC; Luna L; Leeder S
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1065-70. PubMed ID: 3093518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final height in sexually precocious girls after therapy with an intranasal analogue of gonadotrophin-releasing hormone (buserelin).
    Stasiowska B; Vannelli S; Benso L
    Horm Res; 1994; 42(3):81-5. PubMed ID: 7995616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH; Hendry WF; Whitfield HN; Oliver RT
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 18. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist.
    Tuvemo T; Gustafsson J; Proos LA;
    Horm Res; 2002; 57(1-2):27-31. PubMed ID: 12006716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations.
    Ferrari V; Zaniboni A; Simoncini E; Marpicati E; Montini E; Moretti R; Marini G
    Chemioterapia; 1988 Dec; 7(6):414-9. PubMed ID: 3146444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK; Jacobi GH
    Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.